Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-05-27

Study Completion Date

2017-03-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety and pharmacokinetics of UV-4B oral solution when administered to healthy subjects three times a day (TID) for 7 days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects

NCT02061358

Viral Infection

COMPLETED PHASE1

A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine

NCT05067933

COVID-19

TERMINATED PHASE2

Safety Study of Single Administration Intravenous Treatment for Influenza

NCT01375985

Influenza

TERMINATED PHASE1

Safety And Pharmacokinetics Study Of PF-04287881 In Healthy Adults

NCT00793000

Respiratory Tract Infections

COMPLETED PHASE1

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Deuremidevir Hydrobromide for Suspension

NCT06328400

Respiratory Syncytial Virus Infections

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a phase 1, randomized, double-blind, placebo-controlled multiple-ascending dose study to evaluate the safety and pharmacokinetics of UV-4B oral solution when administered to healthy subjects TID for 7 days. Three cohorts of 8 subjects each (6 active, 2 placebo) are planned and up to 2 additional cohorts may be added pending safety review of the initial cohorts. Safety review will occur after each cohort. Safety is evaluated through Day 15 on the basis of adverse event (AE) monitoring, clinical laboratory testing (hematology, serum chemistry, coagulation, urinalysis), vital signs, physical examinations (PE), electrocardiograms (ECG), and fecal occult blood testing. Blood samples are collected at specified intervals up to Day 10 for pharmacokinetic assessment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Viral Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1 - 30 mg

Subjects receiving UV-4B 30 mg oral solution or placebo

Group Type EXPERIMENTAL

UV-4B 30 mg oral solution

Intervention Type DRUG

UV-4B 30 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days

Placebo

Intervention Type DRUG

Placebo oral solution administered TID (every 8 ± 0.5 hours) for 7 days

Cohort 2 - 75 mg

Subjects receiving UV-4B 75 mg oral solution or placebo

Group Type EXPERIMENTAL

UV-4B 75 mg oral solution

Intervention Type DRUG

UV-4B 75 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days

Placebo

Intervention Type DRUG

Placebo oral solution administered TID (every 8 ± 0.5 hours) for 7 days

Cohort 3 - 150 mg

Subjects receiving UV-4B 150 mg oral solution or placebo

Group Type EXPERIMENTAL

UV-4B 150 mg oral solution

Intervention Type DRUG

UV-4B 150 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days

Placebo

Intervention Type DRUG

Placebo oral solution administered TID (every 8 ± 0.5 hours) for 7 days

Cohort 4 - X mg (dose to be determined)

Subjects receiving UV-4B X mg (dose to be determined) oral solution or placebo

Group Type EXPERIMENTAL

UV-4B X mg (dose to be determined) oral solution

Intervention Type DRUG

UV-4B X mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days

Placebo

Intervention Type DRUG

Placebo oral solution administered TID (every 8 ± 0.5 hours) for 7 days

Cohort 5 - Y mg (dose to be determined)

Subjects receiving UV-4B Y mg (dose to be determined) oral solution or placebo

Group Type EXPERIMENTAL

UV-4B Y mg (dose to be determined) oral solution

Intervention Type DRUG

UV-4B Y mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days

Placebo

Intervention Type DRUG

Placebo oral solution administered TID (every 8 ± 0.5 hours) for 7 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

UV-4B 30 mg oral solution

UV-4B 30 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days

Intervention Type DRUG

UV-4B 75 mg oral solution

UV-4B 75 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days

Intervention Type DRUG

UV-4B 150 mg oral solution

UV-4B 150 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days

Intervention Type DRUG

UV-4B X mg (dose to be determined) oral solution

UV-4B X mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days

Intervention Type DRUG

UV-4B Y mg (dose to be determined) oral solution

UV-4B Y mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days

Intervention Type DRUG

Placebo

Placebo oral solution administered TID (every 8 ± 0.5 hours) for 7 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Nonsmoking, healthy male or female subject aged 18 to 45 years, inclusive.
* Female subject is not pregnant and not lactating.
* (Female subjects only who are not postmenopausal or sterile) agreement to use hormonal contraception OR intrauterine device PLUS barrier contraception (condom or occlusive cap such as a diaphragm or surgical vault cap) AND spermicidal foam/gel/cream/suppository starting at least 14 days before the first dose and continuing for at least 3 months after the last dose.
* (Male subjects only) agreement to use barrier contraception during sexual intercourse and to also refrain from sperm donation from the first day of dosing until 3 months after the last dose of the study product.
* Body weight within 60 to 90 kg, inclusive, and body mass index between 18 to 32 kg/m², inclusive.
* Agreement to avoid strenuous exercise starting 4 days before the start of dosing through the period of confinement in the clinical unit and for at least 96 hours before the follow-up visits.

Exclusion Criteria

* History of allergy to drugs in the iminosugar class.
* Treatment with any investigational products or therapies within 30 days (or 5 half-lives, whichever is greater) before the first day of dosing.
* Current or past history of disease/dysfunction of the pulmonary, cardiovascular, endocrine, hematologic, neurological, immune, gastrointestinal genitourinary, or other body system.
* Abnormalities on physical examination suggestive of conditions that may pose an increased risk to the subject; abnormal electrocardiogram results (excluding benign conditions); and Grade 1 or higher abnormalities in vital signs at screening and Grade 2 or higher abnormalities in vital signs at check-in based on a modified version of the FDA Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.
* Clinical laboratory tests outside the normal range at screening and Grade 2 or higher at check-in to the clinical unit.
* Creatinine clearance \< 90 mL/min (based on Cockcroft-Gault equation).
* Proteinuria greater than or equal to 1+.
* Any known or expected risk of bleeding.
* Scheduled surgical procedure during study participation.
* History of alcohol and/or drug abuse within 1 year prior to dosing and/or a positive urine drug screen for substances of abuse at screening or check-in. Urine alcohol above 50 mg/dL.
* Plasma or blood donation within 30 days before the first day of dosing or intention to donate within 30 days after the final day of dosing.
* Treatment with any medication, either prescription or nonprescription, including dietary supplements or herbal medications, within 14 days before dosing (within 30 days before dosing for hepatic or renal clearance-altering agents) and is unable to refrain from any medication during the study period. Exceptions are acetaminophen (not more than 2 g/day), vitamin products at recommended daily doses or hormonal birth control.
* Positive serology test for HIV antibodies, hepatitis B surface antigen, or hepatitis C virus antibody at screening.
* History of relevant food allergies (ie, eggs or other components of standard clinic meals) or unwilling to comply with diet restrictions.
* Psychological and/or emotional problems which would render the informed consent invalid, or limit the ability of the subject to comply with the study requirements;
* Concurrent enrollment in any other clinical trial within 30 days.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes